Blog
How it works
Services
Sign In
Homepage
Blog
How it works
Services
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
GERN.US
id: 267, Created by Stan Vick Chase, Scout

Geron Corporation

Settled
0 joined
100 goal
At 100 participants, legal proceedings can be initiated!
19 March 2018
Class period Start
26 September 2018
Class period End
16 February 2023
Claim deadline
Julia Junge and Richard Junge v. Geron Corporation and John A. Scarlett.
" Lead Plaintiffs, on behalf of the Class, allege that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Lead Plaintiffs allege that Defendants, along with Geron’s development partner, Janssen Biotech Inc. (“Janssen”), a division of Johnson & Johnson, were conducting a Phase 2 clinical trial called IMbark on Geron’s only drug candidate, imetelstat. It is alleged that during the Class Period, Defendants made materially false and misleading statements to investors, and failed to disclose material facts Defendants had a duty to disclose to make their representations not misleading, concerning certain study data results from the IMbark study and certain risk factors. The Complaint alleges that Defendants should have disclosed the allegedly bad news about the IMbark study data when they disclosed allegedly good news about the study. Allegedly, when the truth was disclosed at the end of the Class Period, Geron’s stock declined by over 71%."
Alleged Offence
Other
Suspected Party
Other
Security Type
Stocks
Trade Direction
Long
Lead plaintiff
Johnson Fistel, LLP
Attorney
Kaplan Fox & Kilsheimer LLP
Court
Northern District of California
Judge
Hon. William Alsup
Administrator
EPIQ
Settlement conditions
$14000000 by cash, and $7000000 by Securities
+$24,000,000
Total Settlement Amount
Created by Stan Vick Chase, Scout

Geron Corporation

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a ...

    Ticker
    GERN.US
    ISIN
    US3741631036
    CIK
    886744
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    919 East Hillsdale Boulevard, Foster City, CA, United States, 94404